The Center For Drug Evaluation Of The China National Medical Products Administration Has Accepted For Review The Regulatory Application Of GSK's Shingrix (Recombinant Zoster Vaccine) For The Prevention Of Shingles (Herpes Zoster) In Adults
Portfolio Pulse from Benzinga Newsdesk
The China National Medical Products Administration's Center For Drug Evaluation has accepted GSK's regulatory application for Shingrix, a vaccine for preventing shingles in adults.
February 06, 2024 | 8:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's Shingrix vaccine for shingles prevention in adults is under review by the China National Medical Products Administration, potentially opening a significant market.
The acceptance of GSK's Shingrix vaccine for review by the China National Medical Products Administration is a positive development for GSK, indicating potential market expansion and revenue growth in China. This news is likely to be viewed favorably by investors, potentially leading to a short-term uptick in GSK's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90